Vanda Pharmaceuticals at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Vanda Pharmaceuticals at ASHG 2026 in Montréal: 2 presentations (2 posters).

Organization	ASHG 2026 Attendance
Vanda Pharmaceuticals Washington, District of Columbia	1 Clinical Research Scientist · 1 Head of Genetics
vandapharma.com\|LinkedIn Public company~533 people Vanda develops and commercializes innovative therapies for patients with high unmet medical needs. Its portfolio includes psychiatric, sleep, and motion-sickness medicines. NEREUS, Vanda's motion-sickness vomiting drug, went on sale in Q2 2026, adding a new commercial product. › NEREUS, Vanda's motion-sickness vomiting drug, went on sale in Q2 2026, adding a new commercial product. 2026-08 · source FDA approved Vanda's BYSANTI for bipolar I disorder and schizophrenia, a second new approved drug this year. 2026-02 · source Source: company newsroom Q2 2026 sales $50.5M, down 4%; FY26 guidance $240-290M › Sales dipped slightly even with two new launches; guidance implies growth ahead. · 2026-08-05 “Total net product sales were $50.5 million in Q2 2026, a 4% decrease compared to $52.6 million in Q2 2025. \| Full-year 2026 total revenue guidance of $240-$290 million” Source: results release Currently hiring › Source: careers page	Poster Wed Oct 21 2:30 pm Part of Complex Traits and Polygenic Disorders Poster Wednesday Session PELP1 -coactivator of estrogen receptor is potentially associated with Motion Sickness related vomiting Exhibit & Poster Hall · Board 8306W Statistical geneticsComplex traitsNeurogenetics Poster Thu Oct 22 4:15 pm Part of Genetic Therapies and Precision Medicine Poster Thursday Session First-in-Class Allele-Specific ASO Targeting SNCA p.A53T for Parkinson’s Disease Exhibit & Poster Hall · Board 5009T Rare variantsMolecular therapeutics

Organization

ASHG 2026 Attendance

Vanda Pharmaceuticals

Washington, District of Columbia

1 Clinical Research Scientist · 1 Head of Genetics

vandapharma.com|LinkedIn

Public company~533 people

Vanda develops and commercializes innovative therapies for patients with high unmet medical needs. Its portfolio includes psychiatric, sleep, and motion-sickness medicines.

NEREUS, Vanda's motion-sickness vomiting drug, went on sale in Q2 2026, adding a new commercial product.

›

NEREUS, Vanda's motion-sickness vomiting drug, went on sale in Q2 2026, adding a new commercial product.

2026-08 · source

FDA approved Vanda's BYSANTI for bipolar I disorder and schizophrenia, a second new approved drug this year.

2026-02 · source

Source: company newsroom

Q2 2026 sales $50.5M, down 4%; FY26 guidance $240-290M

›

Sales dipped slightly even with two new launches; guidance implies growth ahead. · 2026-08-05

“Total net product sales were $50.5 million in Q2 2026, a 4% decrease compared to $52.6 million in Q2 2025. | Full-year 2026 total revenue guidance of $240-$290 million”

Source: results release

Currently hiring

›

Source: careers page

Poster

Wed Oct 21
2:30 pm

Part of Complex Traits and Polygenic Disorders Poster Wednesday Session

PELP1 -coactivator of estrogen receptor is potentially associated with Motion Sickness related vomiting

Exhibit & Poster Hall · Board 8306W

Statistical geneticsComplex traitsNeurogenetics

Poster

Thu Oct 22
4:15 pm